Navigation Links
Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid(R) in Facial Augmentation
Date:5/5/2008

sed of 97.5% sterile water and 2.5% cross-linked polyacrylamide. The Aquamid(R) hydrogel is homogeneous: it contains no microparticles; hence its filling effect is due solely to the injected volume. Unlike particle-based fillers, the hydrogel does not rely on an intended foreign body reaction to achieve the desired augmentation. Therefore, the filling effect is immediate and predictable. Moreover, the hydrogel does not cause tissue hardening or fibrosis. No skin test is needed before treatment.

The hydrogel integrates completely into the tissue and does not migrate from the injection site. It stays soft, feels like a natural part of the tissue and follows tissue movements. Because the hydrogel does not degrade over time, it provides augmentation that lasts for years.

Aquamid(R) is available in 40 countries worldwide and is under clinical investigation in the United States. Aquamid is being studied in a double-blind, randomized, multi-center, 2-arm parallel study involving 315 patients in 13 centers comparing the effectiveness of Aquamid(R) and Restylane(R) for the aesthetic treatment of facial wrinkles/folds. Data from this trial will support a PMA application with the FDA.

About Aquamid(R)

Aquamid(R) is a soft volume filler that gives a natural look and feel. Produced using Contura's patented hydrogel technology, Aquamid(R) is composed of 97.5% sterile water and 2.5% cross-linked polyacrylamide. Aquamid(R) was approved in Europe in 2001 and is available in 40 countries worldwide. Over 300,000 Aquamid(R) injections have been performed to date. It is currently under clinical investigation in the U.S. for the aesthetic treatment of facial wrinkles/folds. Aquamid(R) is not approved for sale in the United States.

About Contura

Contura is a medical technology company based in Denmark that develops and commercializes soft tissue fillers. Contura's products -- Aquamid(R) for facial contouring and Bulkamid(R) for the treatment of fe
'/>"/>

SOURCE Contura
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. N30 Pharma Announces Completion of Phase 1 Clinical Studies With N30-201
2. Senetek PLC Announces Positive Results from Pyratine-6(TM) Clinical Trial in Patients with Acne Rosacea
3. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
4. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
5. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
6. Clinical Impact of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology
7. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
8. Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine
9. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
10. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
11. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  MEDIMETRIKS PHARMACEUTICALS today ... William Resnick have been elected to Medimetriks, ... Mr. Lary, who will serve on Medimetriks, ... investment experience to the Company.  Mr. Lary is ... LLC, a leading institutional investment firm.  Mr. Lary ...
(Date:9/23/2014)... YORK , September 23, 2014 ... pioneer in computer-aided dysmorphology analysis will exhibit at the ... Diego, CA. FDNA will present the latest ... and reference solution, using facial analysis technology. Face2Gene facilitates ... of human malformations from facial photos. The ...
(Date:9/23/2014)... 23, 2014 According to ... Product (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave), Application ... - Global Forecasts to 2019", published by MarketsandMarkets, studies ... period of 2014 to 2019. The market is ... CAGR of 9.6% from 2014 to 2019. ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2FDNA to Exhibit at ASHG2014 Presenting Face2Gene Integrated With London Medical Databases (LMD) Online 2Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 4
... Terumo Heart, Inc. today announced that NewYork-Presbyterian Hospital/ ... second U.S. center, and first in the Northeast, ... part of the DuraHeart Bridge-To-Transplant U.S. pivotal trial, ... in up to 40 centers nationwide. The ...
... The American Medical Association (AMA) Foundation announced today the 28 recipients of ... provides $2,500 grants to medical students, physician residents and fellows to conduct ... are conducting research in the following four categories: , , ... , HIV/AIDS , ...
Cached Medicine Technology:Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient 2Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient 3AMA Foundation Announces Seed Grant Research Recipients 2AMA Foundation Announces Seed Grant Research Recipients 3
(Date:9/23/2014)... 23, 2014 Dr. Connie Casad has announced ... to new office space at 12200 Park Central Drive, Suite ... office will be Park Cities Aesthetics, Optimal Health and Wellness, ... announcing her move, Dr. Casad said, “The patients’ comfort and ... select, we want them to always feel like their needs ...
(Date:9/23/2014)... rapidly developing, bringing with its advances promises of ... and treatment interventions. Genetic tests are already ... and hepatitis c virus (HPC), and emerging research ... screen for an individual,s susceptibility to addiction to ... , While there appear to be many benefits ...
(Date:9/23/2014)... -- Few children who take medication for attention-deficit/hyperactivity ... rates vary six-fold across counties in the United ... can manage symptoms for many children with ADHD, ... behavioral therapy (psychotherapy), the Rand Corp. researchers noted. ... 1,500 counties across the United States that included ...
(Date:9/23/2014)... Ill. (September 23, 2014) Both patients and ... screening computed tomography (CT) colonography greatly outweighs the ... tests precipitated by false-positive diagnoses, according to a ... the journal Radiology . , Diagnostic tests ... specific organ. However, when screening for colorectal cancer ...
(Date:9/23/2014)... SOURCE: Solutions from Our Country’s ... made to Rimidi Diabetes and TruClinic ... business solutions to challenges faced by patients and healthcare ... between The Hitachi Foundation, Village Capital, ... with the investment capital, mentoring, and support needed to ...
Breaking Medicine News(10 mins):Health News:Dr. Connie Casad Moving to New Office Location 2Health News:NYU-Mount Sinai Beth Israel study explores drug users' opinions on genetic testing 2Health News:Kids Taking ADHD Drugs Get Little Psychotherapy: Study 2Health News:Patients accept false-positives to achieve diagnostic sensitivity 2Health News:Patients accept false-positives to achieve diagnostic sensitivity 3Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 2Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 3Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 4Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 5
... ... Shows Pointing to Words During Story Time Enhances Children,s Literacy Development , ... Rockville, MD (Vocus) May 4, 2010 -- While ... study suggests that by pointing to the words being read and talking about print, children,s ...
... , ... Show How Women Health Workers Can Save Children,s Lives, Fill Key Health Care Gaps Around the ... Westport, Conn. (Vocus) -- To ... child deaths, countries must invest in women who are front-line health care workers, Save the Children ...
... be an effective preventive measure, researchers say , TUESDAY, May ... be one way to slow the HIV/AIDS epidemic, according to ... greater risk for HIV infection than those not infected with ... 18 to 24, who were uncircumcised, did not have HIV ...
... 4, 2010) Rates of colorectal cancer screening vary ... to data being presented at Digestive Disease Week (DDW) ... as well as utilization rates of virtual and optical ... DDW is the largest international gathering of physicians ...
... ... of the best hospitals and clinics in the world. , ... Monsey, NY (PRWEB) May 4, 2010 -- The new All Time Medical space ... were physically bound by how many people we were able to hire. We literally couldn,t have ...
... The ... provider while more accurately reflecting its strengths and abilities , ... Baltimore, MD (PRWEB) May 4, 2010 -- ... America, is pleased to announce the completion of its rebranding, establishing itself as Tax ...
Cached Medicine News:Health News:New Study Shows Parents How to Increase Their Kid's Success in Reading 2Health News:For a Mother's Day Gift with Lasting Appeal, Invest in Women Health Workers, Says Save the Children 2Health News:For a Mother's Day Gift with Lasting Appeal, Invest in Women Health Workers, Says Save the Children 3Health News:For a Mother's Day Gift with Lasting Appeal, Invest in Women Health Workers, Says Save the Children 4Health News:Men With HPV at Higher Risk for HIV, Study Finds 2Health News:Investigators examine colorectal cancer screening methods among diverse populations 2Health News:Investigators examine colorectal cancer screening methods among diverse populations 3Health News:Investigators examine colorectal cancer screening methods among diverse populations 4Health News:Investigators examine colorectal cancer screening methods among diverse populations 5Health News:Investigators examine colorectal cancer screening methods among diverse populations 6Health News:Investigators examine colorectal cancer screening methods among diverse populations 7Health News:Investigators examine colorectal cancer screening methods among diverse populations 8Health News:Investigators examine colorectal cancer screening methods among diverse populations 9Health News:Investigators examine colorectal cancer screening methods among diverse populations 10Health News:All Time Medical Has Just Moved To Their New, State-Of-The Art Office Situated In The Heart Of The Business District Of Monsey, N.Y 2Health News:Nationwide Tax Solutions Rebrands Itself as Tax Strategies 2
... scaleable device that works with ... plasma or buffy coat. The ... must be prepared independently using ... volume and concentration factor can ...
Avitene Microfibrillar Collagen (MCH) is used in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical....
The Ultrafoam Collagen Sponge is indicated in all surgical procedures as an adjunct to hemostasis when control by ligature or conventional procedures are ineffective or impractical....
Exclusive oxidized regenerated cellulose technology. The only oxidized regenerated cellulose hemostat line, surgicel absorbable hemostat delivers a unique combination of effectiveness, absorbability,...
Medicine Products: